Hepamerz (L-Ornithine L-Aspartate) Infusion in Non-Alcoholic Hepatic Encephalopathy

What is Hepamerz?

Mechanism of Action

1. Urea Cycle Stimulation (periportal hepatocytes)

• Ornithine is a key intermediate and activator of the urea cycle. It activates carbamoyl phosphate synthetase I (CPS-I), the rate-limiting enzyme, driving conversion of NH3 → urea.
• Aspartate acts as a nitrogen donor in the cycle, combining with citrulline to form argininosuccinate.

2. Glutamine Synthesis (perivenous hepatocytes + skeletal muscle)

• In remaining functional hepatocytes and in skeletal muscle, ornithine and aspartate serve as substrates for glutamine synthetase.
• NH3 + glutamate → glutamine (a non-toxic transport form of ammonia, excreted by kidneys).
• This pathway is particularly important when the urea cycle capacity is reduced due to advanced liver disease.

Classification of Hepatic Encephalopathy

Dosing and Administration

Intravenous (Infusion) - Hepamerz Concentrate

• Standard adult dose: 20-40 g IV per day, diluted in 500 mL of 5% dextrose or normal saline, administered over 4-8 hours (max infusion rate: 5 g/hour to avoid nausea/vomiting)
• For acute/severe OHE (Grade III-IV): 30 g/24 hours as a continuous infusion for 5 days - this regimen was used in the landmark 2022 RCT (PMID: 34822189)
• Duration: Typically 5-7 days for acute episodes; may be extended
• Dilution: Each ampoule (10 g/10 mL or 10 g/20 mL) must be diluted - never administer undiluted

Oral Sachets (maintenance/MHE)

• 3 g sachets, 3 times daily with meals

Clinical Evidence

In Overt/Severe HE (Grade III-IV)

• Design: 140 cirrhotic patients with OHE Grade III-IV randomized to LOLA 30 g/24h continuous IV infusion + lactulose + rifaximin vs. placebo + lactulose + rifaximin
• Results:
  • HE grade improvement: 92.5% vs. 66% (p < 0.001) - LOLA group markedly superior
  • Time to recovery: 2.70 ± 0.46 vs. 3.00 ± 0.87 days (p = 0.03) - faster recovery
  • 28-day mortality: 16.4% vs. 41.8% (p = 0.001) - dramatic mortality benefit
  • Significant reductions in ammonia, IL-6, and TNF-alpha in LOLA group
• Conclusion: LOLA + lactulose + rifaximin combination superior to lactulose + rifaximin alone

IV vs. Oral LOLA Comparison

• Mean ammonia reduction Day 1 to Day 5: 55.4 µmol/L (IV) vs. 60.75 µmol/L (oral) - no significant difference (p = 0.511)
• Both routes equally effective in HE grade improvement
• Both significantly reduced ammonia within each group (p < 0.001)
• Implication: IV route preferred in obtunded/comatose patients who cannot take oral medications; once conscious, can transition to oral

In Minimal Hepatic Encephalopathy (MHE)

• LOLA superior to placebo in reversing MHE (RR = 2.26, 95% CI: 1.53-3.35)
• LOLA prevented progression to OHE (RR = 0.22, 95% CI: 0.076-0.637)
• Oral LOLA appeared slightly more effective than IV for MHE reversal in subgroup analysis
• No mortality benefit shown in this MHE population (expected, as MHE is early stage)

LOLA + Lactulose Combination (2025 Meta-analysis)

• LOLA + lactulose combination is 31% more effective than lactulose alone (RR = 1.31, 95% CI: 1.22-1.42)
• Significant reductions in AST, ALT, total bilirubin, and NH3
• Good safety profile

Post-TIPS HE Prevention

Role in Non-Alcoholic Etiology Specifically

1. Pathophysiology is the same - regardless of etiology, the final common pathway of HE involves hyperammonemia, astrocyte swelling, and neuroinflammation. LOLA addresses the ammonia component directly.
2. NAFLD/NASH cirrhosis - these patients often have preserved muscle mass initially, meaning skeletal muscle glutamine synthesis (one of LOLA's mechanisms) may work more effectively.
3. No etiology-specific contraindication - LOLA is used across alcoholic and non-alcoholic etiologies. The Jain 2022 RCT included patients with a wide etiology mix (viral + NAFLD + cryptogenic).
4. Inflammation reduction - IL-6 and TNF-alpha reduction seen with LOLA are particularly relevant in NASH, which has a baseline inflammatory milieu that may exacerbate HE.

Position in Treatment Algorithm

Overt HE (Grade II-IV):
1. Identify & treat precipitants (infection, bleeding, hypokalemia, drugs)
2. Lactulose 30-60 g/day (titrate to 2-3 soft stools/day) - FIRST LINE
3. Add Rifaximin 550 mg BD - especially for recurrence prevention
4. Add LOLA IV infusion (Hepamerz 20-30 g/day) - ADJUNCT, particularly in:
   - Grade III-IV (severe) OHE
   - Post-TIPS HE
   - Inadequate response to lactulose ± rifaximin
   - Unable to take oral medications
5. Branched-chain amino acids - if indicated
6. Treat underlying liver disease / consider transplant evaluation

Safety Profile

• Well tolerated overall
• Nausea/vomiting - most common side effect, especially if infused too rapidly (keep rate ≤ 5 g/hour)
• Contraindicated in severe renal impairment (GFR < 30 mL/min) - risk of glutamine accumulation
• Caution in pregnancy (limited data)
• No significant drug-drug interactions with lactulose or rifaximin

Summary Table

Hepamerz (LOLA) in Acute Liver Failure (ALF)

Short Answer: Use with Caution - NOT Standard of Care

Why ALF is Different from Chronic Liver Disease HE

The Glutamine Paradox - The Core Concern

• Astrocyte glutamine accumulates faster than it can be exported
• Glutamine itself is osmotically active inside astrocytes
• This causes astrocyte swelling - the primary driver of cerebral edema in ALF
• So excess glutamine formation (one of LOLA's mechanisms) can paradoxically worsen cerebral edema

What the Evidence Says

• Plum & Posner's (Stupor and Coma): LOLA is listed for the chronic liver failure state only. For ALF management, the focus shifts to: mannitol for ICP, N-acetylcysteine (in paracetamol-induced ALF), continuous renal replacement therapy (CRRT), and liver transplant evaluation - LOLA is not mentioned.
• Sleisenger & Fordtran (GI & Liver Disease): LOLA is noted to activate the urea cycle and enhance ammonia clearance, with a possible beneficial effect on mortality in HE - but this review evidence is for cirrhotic HE, not ALF specifically.
• INASL Consensus on ALF Management (PMID 33029057): Acknowledges ammonia plays a crucial role and that "the role of newer ammonia-lowering agents is still evolving" in ALF. The emphasis is on early CRRT for ammonia control, lactulose, and transplant - LOLA is not a first-line recommendation.
• Karvellas et al. 2024 ICU Review (PMID 37945461): LOLA is listed among ammonia-targeted strategies in liver failure (alongside laxatives, rifaximin, CRRT) but the review contextualizes this mainly for ACLF, not pure ALF.

Practical Summary: When LOLA Can/Cannot Be Used in ALF

What Should You Use Instead in ALF?

1. Treat the precipitant - N-acetylcysteine (paracetamol), antivirals (HBV), steroids (autoimmune), etc.
2. Lactulose - to reduce gut ammonia production; use cautiously (avoid if ileus or risk of abdominal distension worsening ICP)
3. Rifaximin - oral, safe, reduces ammonia-producing gut flora
4. CRRT (continuous renal replacement therapy) - the most effective ammonia-lowering strategy in ALF with high ammonia/cerebral edema; removes ammonia directly from blood
5. Mannitol / hypertonic saline - for elevated ICP / cerebral edema
6. Avoid sedatives, narcotics, nephrotoxins
7. Early transplant evaluation - the only definitive therapy for poor-prognosis ALF
8. MARS (Molecular Adsorbent Recirculating System) - extracorporeal albumin dialysis; reduces ammonia and improves severe HE in ACLF

Bottom Line

LOLA/Hepamerz is not recommended in true ALF. Its mechanism depends on functional hepatocytes (for the urea cycle) and generates glutamine - which in ALF can worsen the cerebral edema that kills these patients. The priority in ALF-HE is CRRT, ICP management, and liver transplantation. LOLA has a role in chronic cirrhotic HE and ACLF, but not in hyperacute/acute liver failure.

• Sleisenger & Fordtran's GI and Liver Disease, p. 1817 | Plum & Posner's Stupor and Coma, p. 626-628 | INASL ALF Consensus, PMID 33029057

Acute Liver Failure (ALF) - Definition

Core Definition

1. Severe acute liver injury (hepatocyte necrosis/dysfunction)
2. Coagulopathy - INR > 1.5
3. Hepatic encephalopathy (HE) - any grade

"Acute liver failure is defined as a severe acute liver injury that precipitates the sudden onset of encephalopathy and coagulopathy (INR > 1.5). By definition, acute liver failure results from an insult within the prior 6 months."

• Goldman-Cecil Medicine

"Encephalopathy in the appropriate setting remains the essential requirement for the diagnosis of ALF."

• Sleisenger & Fordtran

Classification by Time Course (O'Grady/King's College Classification)

• Fulminant hepatic failure - encephalopathy within 8 weeks of illness onset
• Subfulminant hepatic failure - liver disease up to 26 weeks before encephalopathy

Key Distinguishing Features (vs. Chronic Liver Disease)

"The encephalopathy of acute liver failure is mediated by cerebral edema, not by the portosystemic shunting and portal hypertension of cirrhosis."

• Goldman-Cecil Medicine

Important Nuance: Wilson's Disease and Autoimmune Hepatitis

Causes by Geography

Acute-on-Chronic Liver Failure (ACLF) - Distinction

• Liver failure triggered by an acute insult in a patient with pre-existing liver disease / cirrhosis
• Precipitants: portal hypertensive bleeding, sepsis, acute viral hepatitis superimposed on cirrhosis
• Has a different pathophysiology and prognosis from true ALF

Summary

ALF = Coagulopathy (INR > 1.5) + Hepatic Encephalopathy + No prior chronic liver disease + Onset within 26 weeks Encephalopathy is the sine qua non of the diagnosis. The subtype (hyperacute vs acute vs subacute) depends on the jaundice-to-encephalopathy interval and determines prognosis.

• Goldman-Cecil Medicine, p. 174 | Sleisenger & Fordtran, p. 1836 | Current Surgical Therapy 14e, p. 460